- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 09.10. | Sprint Bioscience CEO comments on deal potential | 2 | Cision News |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | New Core One 3D Printer From Prusa May Be the Answer to Its Bambu Problem | ||
| PALATIN TECHNOLOGIES | 0,865 | +0,70 % | Palatin Technologies Inc. Loss At -$7.82 Mln In Q1 | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced Loss for first quarter of -$7.82 millionThe company's earnings totaled -$7.82 million, or -$0.39 per share. This compares with... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,780 | 0,00 % | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs | Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen | |
| AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
| HALOZYME THERAPEUTICS | 42,910 | -1,20 % | Evotec: Halozyme-Offerte über 11 Euro wirft Fragen auf | Übernahmegerüchte gibt es bei Evotec schon länger. Mit dem Auftauchen des Evotec-Aktienpaketes bei Triton, wir berichteten, schien eigentlich klar, wer der mögliche Kandidat für den zukünftigen Mehrheitsaktionär... ► Artikel lesen | |
| GLOW LIFETECH | 0,029 | -7,94 % | Glow LifeTech Corp.: Glow Lifetech Announces Non-Brokered Private Placement Offering of Units and Debt Settlement | Toronto, Ontario--(Newsfile Corp. - November 5, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it intends to complete a non-brokered... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,500 | -1,50 % | AbCellera Reports Q2 2024 Business Results | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 309,90 | +0,91 % | Bio-Rad Reports Third-Quarter 2024 Financial Results | HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results... ► Artikel lesen | |
| AVID BIOSERVICES | 11,500 | 0,00 % | Avid Bioservices, Inc. (CDMO): A Bull Case Theory | ||
| BIOLINERX | 0,356 | -31,54 % | BioLineRx inks licensing deal, share purchase agreement | ||
| MINERVA NEUROSCIENCES | 1,980 | -2,94 % | Aktie von Minerva Neurosciences erreicht 52-Wochen-Tief bei 2,25 US-Dollar | ||
| GEOVAX LABS | 2,685 | 0,00 % | GeoVax meldet Fortschritte bei Studie zu CLL-Impfstoff-Booster | ||
| AADI BIOSCIENCE | 2,060 | -2,83 % | Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update | FYARRO® sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth
Aadi continues to focus on FYARRO commercial business and comprehensive strategic... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 8,835 | -4,49 % | Pre-market Movers: Portage Biotech, Veea, Intuitive Machines, Applied Therapeutics, Galmed Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Portage Biotech Inc. (PRTG) is up over 179% at... ► Artikel lesen | |
| OVID THERAPEUTICS | 0,940 | -5,53 % | Ovid Therapeutics Inc.: Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth | NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions... ► Artikel lesen |
SPRINT BIOSCIENCE AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,109 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.
